- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Weekly Roundup: March 8-12, 2021
ICYMI, some of this week’s featured content includes stories on how mask usage worsens rosacea, why trichometric analysis is the key to finding an effective hair loss treatment, why some acne treatments are targeting the sebaceous gland, and more.
POLL: What is your preferred acne treatment?
The Mainstream Patient: March 8, 2021
This week’s edition of The Mainstream Patient features stories on dermaplaning, active skincare ingredients, the history of Botox, plus more.
Quantifying is Key to Effective Hair Loss Treatment
Trichometric analysis helps evaluate whether treatment is working for patients experiencing hair loss and what adjustments need to be made to the regimen.
Sebaceous Gland is Target for Acne Treatments
Recently approved treatments for acne are focused on decreasing activity within the sebaceous gland.
New Research Addresses Rosacea Challenges
Update tracks trending factors changing the treatment landscape.
Systemic Therapy Advances for AD
The limited armamentarium of systemic therapies for atopic dermatitis has already been expanded with the approval of dupilumab. Forthcoming systemic therapies are expected to include a new biologic and three new Janus kinase (JAK) inhibitors.
Tildrakizumab Sustains Disease Control Over 5 Years in Phase 3 Studies
Sun Pharmaceuticals announces the publication of results from its 5-year extension studies evaluating the safety, efficacy and tolerability of tildrakizumab-asmn.
Study: Mask Usage Worsens Rosacea
Recent research shows prolonged face-mask usage leads to negative quality-of-life impact and worsening of disease for rosacea.
Ruxolitinib Cream NDA Accepted for Priority Review by FDA
Incyte announces the FDA has accepted the NDA for ruxolitinib cream for priority review. Ruxolitinib cream is a topical selective janus kinase (JAK)1/JAK2 inhibitor intended for the treatment of atopic dermatitis.
